IONETIX and PRECISION MOLECULAR Inc. Announce Supply Agreement for Astatine-211
IONETIX Corporation (USA), a radiopharmaceutical solution provider
focusing on establishing a secure supply chain for alpha-emitting
radiopharmaceuticals recently announced it has signed a supply agreement for
the therapeutic radioisotope astatine-211 (211At) with Precision
Molecular, Inc. (PMI), a clinical-stage company developing targeted
radiopharmaceuticals and theranostics for patients with cancer.
PMI is developing an astatine-211 labeled
inhibitor of prostate-specific membrane antigen (PSMA) known as PMI21. PMI21 is
designed to target PSMA, which is present at low levels in normal prostate
tissue, but is markedly elevated in prostate cancer cells. The PSMA-binding and
211At labeling functions of PMI21 have been optimized in combination
for high tumor uptake and rapid clearance from normal tissues in order to
maximize potency and minimize toxicity. PMI plans to advance PMI21 into
clinical trials in patients with metastatic prostate cancer later this year.
To
read more please visit:
Source: IONETIX